Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 19Lymphoma, Mantle-Cell 9Lymphoma, Non-Hodgkin 4Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Waldenstrom Macroglobulinemia 2Recurrence 2Pancreatic Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Pyloric Stenosis, Hypertrophic 1Ovarian Neoplasms 1Neoplasm, Residual 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Hairy Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Glioblastoma 1DLBCL 1Chromosome 17 deletion 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Anemia, Hemolytic, Autoimmune 1Advanced Haematological Malignancies 1

Interventions

Rituximab 49fludarabine phosphate 32Cyclophosphamide 30Whole-Body Irradiation 26Peripheral Blood Stem Cell Transplantation 25Mycophenolic Acid 24Tacrolimus 19Cyclosporine 16Dexamethasone 13Busulfan 13ibrutinib 12Sirolimus 12Bortezomib 11Antilymphocyte Serum 11Melphalan 10Etoposide 10Calcium Dobesilate 10Methotrexate 8Lenalidomide 8Cyclosporins 8idelalisib 7Everolimus 6Indium 5Filgrastim 5thymoglobulin 4ibritumomab tiuxetan 4carfilzomib 4Vincristine 4Prednisone 4In Situ Hybridization, Fluorescence 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Waldenstrom Macroglobulinemia × acalabrutinib × Clear all
NCT02362035 2026-05-13

KEYNOTE145

Acerta Pharma BV

Phase 1/2 Completed
161 enrolled 29 charts
LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02180724 2026-03-20

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Acerta Pharma BV

Phase 2 Active not recruiting
107 enrolled 15 charts
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡